Cargando…
Suppression of Autoimmune Retinal Inflammation by an Antiangiogenic Drug
Chronic and recurrent uveitis account for approximately 10% of legal blindness in the western world. Autoimmune uveitis is driven by activated CD4(+) T cells that differentiate into effector T helper cells (Th1, Th2, and Th17) which release proinflammatory cytokines that damage the retina. In this s...
Autores principales: | Yoshimura, Takeru, Benny, Ofra, Bazinet, Lauren, D’Amato, Robert J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681944/ https://www.ncbi.nlm.nih.gov/pubmed/23785488 http://dx.doi.org/10.1371/journal.pone.0066219 |
Ejemplares similares
-
Broad Spectrum Antiangiogenic Treatment for Ocular Neovascular Diseases
por: Benny, Ofra, et al.
Publicado: (2010) -
Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits
por: Verheul, H M W, et al.
Publicado: (1999) -
Autoimmune hepatitis or drug‐induced autoimmune hepatitis following Covid‐19 vaccination?
por: Fimiano, Federica, et al.
Publicado: (2022) -
A Method for Developing Novel 3D Cornea-on-a-Chip Using Primary Murine Corneal Epithelial and Endothelial Cells
por: Bai, Jing, et al.
Publicado: (2020) -
Treatment of retinal pigment epithelial detachment with antiangiogenic therapy
por: Arias, Luis
Publicado: (2010)